Revisión Sistematica sobre el Diagnostico Diferencial y Manejo de 2 Entidades Dentro del Mismo Espectro de las Toxicodermias Graves, Stevens–Johnson y Necrolisis Epidérmica Toxica
Resumen
El síndrome de Stevens-Johnson (SSJ) y la necrólisis epidérmica tóxica (NET) son enfermedades raras que se caracterizan por necrosis epidérmica generalizada y desprendimiento de la piel. Se asocian con una morbilidad y mortalidad significativas, y el diagnóstico y tratamiento tempranos son fundamentales para lograr resultados favorables para los pacientes. En esta revisión se abordaran los avances recientes en el diagnóstico y tratamiento de la enfermedad. Se identificaron múltiples proteínas (galectina 7 y RIP3) que son biomarcadores poNETciales prometedores para SSJ/NET, aunque ambos aún se encuentran en fases iniciales de investigación. En cuanto al tratamiento, la ciclosporina es la terapia más eficaz para el tratamiento del SSJ, y una combinación de inmunoglobulina intravenosa (IVIg) y corticosteroides es más eficaz para la superposición SSJ/NET y NET. Debido a la naturaleza rara de la enfermedad, hay una falta de ensayos controlados aleatorios prospectivos y realizarlos en el futuro proporcionaría información valiosa sobre el tratamiento de esta enfermedad.
Descargas
Citas
Duong T.A., Valeyrie-Allanore L., Wolkenstein P., Chosidow O. Severe cutaneous adverse reactions to drugs. Lancet. 2017;390:1996–2011. doi: 10.1016/S0140-6736(16)30378-6. (PubMed) (CrossRef) (Google Scholar)
Frey N., Jossi J., Bodmer M., Bircher A., Jick S., Meier C.R., Spoendlin J. The Epidemiology of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in the UK. J. Investig. Dermatol. 2017;137:1240–1247. doi: 10.1016/j.jid.2017.01.031. (PubMed) (CrossRef) (Google Scholar)
Hsu D., Brieva J., Silverberg N.B., Silverberg J. Morbidity and Mortality of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults. J. Investig. Dermatol. 2016;136:1387–1397. doi: 10.1016/j.jid.2016.03.023. (PubMed) (CrossRef) (Google Scholar)
Yang M.-S., Lee J.Y., Kim J., Kim G.-W., Kim B.-K., Kim J.-Y., Park H.-W., Cho S.-H., Min K.-U., Kang H.-R. Incidence of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Nationwide Population-Based Study Using National Health Insurance Database in Korea. PLoS ONE. 2016;11:e0165933. doi: 10.1371/journal.pone.0165933. (PMC free article) (PubMed) (CrossRef) (Google Scholar)
Hsu D.Y., Brieva J., Silverberg N.B., Paller A.S., Silverberg J.I. Pediatric Stevens-Johnson syndrome and toxic epidermal necroly-sis in the United States. J. Am. Acad. Dermatol. 2017;76:811–817.e4. doi: 10.1016/j.jaad.2016.12.024. (PMC free article) (PubMed) (CrossRef) (Google Scholar)
Paulmann M., Mockenhaupt M. Severe skin reactions: Clinical picture, epidemiology, etiology, pathogenesis, and treatment. Allergo J. Int. 2019;28:311–326. doi: 10.1007/s40629-019-00111-8. (CrossRef) (Google Scholar)
Lim V.M., Do A., Berger T.G., Nguyen A.H., Deweese J., Malone J.D., Jordan K., Hom F., Tuffanelli L., Fillari P., et al. A decade of burn unit experience with Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: Clinical pathological diagnosis and risk factor awareness. Burns. 2016;42:836–843. doi: 10.1016/j.burns.2016.01.014. (PubMed) (CrossRef) (Google Scholar)
Lissia M., Mulas P., Bulla A., Rubino C. Toxic epidermal necrolysis (Lyell’s disease) Burns. 2010;36:152–163. doi: 10.1016/j.burns.2009.06.213. (PubMed) (CrossRef) (Google Scholar)
Richer V., Bouffard D., Belisle A., Duranceau L., Perreault I., Provost N. Acute blistering diseases on the burn ward: Beyond Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis. Burns. 2013;39:1290–1296. doi: 10.1016/j.burns.2013.02.009. (PubMed) (CrossRef) (Google Scholar)
Sekula P., Dunant A., Mockenhaupt M., Naldi L., Bavinck J.N.B., Halevy S., Kardaun S., Sidoroff A., Liss Y., Schumacher M., et al. Comprehensive Survival Analysis of a Cohort of Patients with Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis. J. Investig. Dermatol. 2013;133:1197–1204. doi: 10.1038/jid.2012.510. (PubMed) (CrossRef) (Google Scholar)
Paggiaro A.O., Silva E., Filho M.L., de Carvalho V.F., Isaac C., Gemperli R. The Role of Biological Skin Substitutes in Ste-vens-Johnson Syndrome: Systematic Review. Plast. Surg. Nurs. Off. J. Am. Soc. Plast. Reconstr. Surg. Nurses. 2018;38:121–127. (Google Scholar)
Charlton O.A., Harris V., Phan K., Mewton E., Jackson C., Cooper A. Toxic Epidermal Necrolysis and Steven-Johnson Syn-drome: A Comprehensive Review. Adv. Wound Care. 2020;9:426–439. doi: 10.1089/wound.2019.0977. (PMC free article) (PubMed) (CrossRef) (Google Scholar)
Guvenir H., Arikoglu T., Vezir E., Misirlioglu E.D. Clinical Phenotypes of Severe Cutaneous Drug Hypersensitivity Reactions. Curr. Pharm. Des. 2019;25:3840–3854. doi: 10.2174/1381612825666191107162921. (PubMed) (CrossRef) (Google Scholar)
Paulmann M., Mockenhaupt M. Fever in Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis in Pediatric Cases. Pediatr. Infect. Dis. J. 2017;36:513–515. doi: 10.1097/INF.0000000000001571. (PubMed) (CrossRef) (Google Scholar)
Alerhand S., Cassella C., Koyfman A. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in the Pediatric Popula-tion: A Review. Pediatric Emerg. Care. 2016;32:472–478. doi: 10.1097/PEC.0000000000000840. (PubMed) (CrossRef) (Google Scholar)
Grünwald P., Mockenhaupt M., Panzer R., Emmert S. Erythema multiforme, Stevens-Johnson syndrome/Toxic Epidermal Necrolysis—Diagnosis and treatment. JDDG J. Ger. Soc. Dermatol. 2020;18:547–553. doi: 10.1111/ddg.14118. (PubMed) (CrossRef) (Google Scholar)
Shanbhag S., Chodosh J., Fathy C., Goverman J., Mitchell C., Saeed H.N. Multidisciplinary care in Stevens-Johnson syndrome. Ther. Adv. Chronic Dis. 2020;11 doi: 10.1177/2040622319894469. (PMC free article) (PubMed) (CrossRef) (Google Scholar)
Basu S., Shanbhag S.S., Gokani A., Kedar R., Bahuguna C., Sangwan V.S. Chronic Ocular Sequelae of Stevens-Johnson Syndrome in Children: Long-term Impact of Appropriate Therapy on Natural History of Disease. Am. J. Ophthalmol. 2018;189:17–28. doi: 10.1016/j.ajo.2018.01.028. (PubMed) (CrossRef) (Google Scholar)
Gregory D.G. New Grading System and Treatment Guidelines for the Acute Ocular Manifestations of Stevens-Johnson Syn-drome. Ophthalmology. 2016;123:1653–1658. doi: 10.1016/j.ophtha.2016.04.041. (PubMed) (CrossRef) (Google Scholar)
Aghdam M.K., Ahmadiafshar A., Eftekhari K. Toxic epidermal necrolysis syndrome following single-dose diclofenac suppos-itory, a case report. J. Compr. Pediatrics. 2020;11:e100496. (Google Scholar)
Alajmi A., Jfri A., Gomolin A., Jafarian F. A pediatric case of Stevens-Johnson syndrome/Toxic Epidermal Necrolysis with rap-id response to intravenous cyclosporine. JAAD Case Rep. 2020;6:555–557. doi: 10.1016/j.jdcr.2020.04.003. (PMC free article) (PubMed) (CrossRef) (Google Scholar)
Maloney N.J., Ravi V., Cheng K., Bach D.Q., Worswick S. Stevens-Johnson syndrome and Toxic Epidermal Necrolysis-like reac-tions to checkpoint inhibitors: A systematic review. Int. J. Dermatol. 2020;59:e183–e188. doi: 10.1111/ijd.14811. (PubMed) (CrossRef) (Google Scholar)
Simonsen A.B., Kaae J., Ellebaek E., Svane I.M., Zachariae C. Cutaneous adverse reactions to anti–PD-1 treatment—A systematic review. J. Am. Acad. Dermatol. 2020;83:1415–1424. doi: 10.1016/j.jaad.2020.04.058. (PubMed) (CrossRef) (Google Scholar)
Madabhavi I., Revannasiddaiah S., Patel A., Anand A. Toxic epidermal necrolysis with the use of tamoxifen. BMJ Case Rep. 2015;2015:bcr2014209102. doi: 10.1136/bcr-2014-209102. (PMC free article) (PubMed) (CrossRef) (Google Scholar)
Mani R., Monteleone C., Schalock P.C., Truong T., Zhang X.B., Wagner M.L. Rashes and other hypersensitivity reactions associ-ated with antiepileptic drugs: A review of current literature. Seizure. 2019;71:270–278. doi: 10.1016/j.seizure.2019.07.015. (PubMed) (CrossRef) (Google Scholar)
Rashid M., Kashyap A., Undela K. Valproic acid and Stevens-Johnson syndrome: A systematic review of descriptive studies. Int. J. Dermatol. 2019;58:1014–1022. doi: 10.1111/ijd.14411. (PubMed) (CrossRef) (Google Scholar)
Gupta S.S., Sabharwal N., Patti R., Kupfer Y. Allopurinol-Induced Stevens-Johnson Syndrome. Am. J. Med. Sci. 2019;357:348–351. doi: 10.1016/j.amjms.2018.11.018. (PubMed) (CrossRef) (Google Scholar)
Sibbald C., Putterman E., Micheletti R., Treat J., Castelo-Soccio L. Retrospective review of drug-induced Stevens-Johnson syn-drome and Toxic Epidermal Necrolysis cases at a pediatric tertiary care institution. Pediatric Dermatol. 2020;37:461–466. doi: 10.1111/pde.14118. (PubMed) (CrossRef) (Google Scholar)
Sassolas B., Haddad C., Mockenhaupt M., Dunant A., Liss Y., Bork K., Haustein U.F., Vieluf D., Roujeau J.C., Le Louet H., et al. ALDEN, an algorithm for assessment of drug causal-ity in stevens-johnson syndrome and Toxic Epidermal Necrolysis: Comparison with case-control analysis. Clin. Pharmacol. Ther. 2010;88:60–68. doi: 10.1038/clpt.2009.252. (PubMed) (CrossRef) (Google Scholar)
Hasegawa A., Abe R. Recent advances in managing and understanding Stevens-Johnson syndrome and Toxic Epidermal Necrolysis. F1000Research. 2020;9:612. doi: 10.12688/f1000research.24748.1. (PMC free article) (PubMed) (CrossRef) (Google Scholar)
Abe R. Immunological response in Stevens-Johnson syndrome and Toxic Epidermal Necrolysis. J. Dermatol. 2015;42:42–48. doi: 10.1111/1346-8138.12674. (PubMed) (CrossRef) (Google Scholar)
Adam J., Pichler W.J., Yerly D. Delayed drug hypersensitivity: Models of T-cell stimulation. Br. J. Clin. Pharmacol. 2010;71:701–707. doi: 10.1111/j.1365-2125.2010.03764.x. (PMC free article) (PubMed) (CrossRef) (Google Scholar)
Pichler W.J. Modes of presentation of chemical neoantigens to the immune system. Toxicology. 2002;181–182:49–54. doi: 10.1016/S0300-483X(02)00254-8. (PubMed) (CrossRef) (Google Scholar)
Abe R., Shimizu T., Shibaki A., Nakamura H., Watanabe H., Shimizu H. Toxic epidermal necrolysis and Stevens-Johnson syn-drome are induced by soluble fas ligand. Am. J. Pathol. 2003;162:1515–1520. doi: 10.1016/S0002-9440(10)64284-8. (PMC free article) (PubMed) (CrossRef) (Google Scholar)
Chung W.-H., Hung S.-I., Yang J.-Y., Su S.-C., Huang S.-P., Wei C.-Y., Chin S.-W., Chiou C.-C., Chu S.-C., Ho H.-C., et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and Toxic Epidermal Necrolysis. Nat. Med. 2008;14:1343–1350. doi: 10.1038/nm.1884. (PubMed) (CrossRef) (Google Scholar)
Chen C.B., Kuo K.L., Wang C.W., Lu C.W., Chung-Yee H.R., Lu K.L., Chang W.C., Chen W.T., Yun F., NETg Y.C., et al. Detecting Lesional Granulysin Levels for Rapid Di-agnosis of Cytotoxic T lymphocyte–Mediated Bullous Skin Disorders. J. Allergy Clin. Immunol. Pract. 2020;9:1327–1337. doi: 10.1016/j.jaip.2020.09.048. (PubMed) (CrossRef) (Google Scholar)
Abe R., Yoshioka N., Murata J., Fujita Y., Shimizu H. Granulysin as a marker for early diagnosis of the Stevens-Johnson syn-drome. Ann. Intern. Med. 2009;151:514–515. doi: 10.7326/0003-4819-151-7-200910060-00016. (PubMed) (CrossRef) (Google Scholar)
Saito N., Abe R., Yoshioka N., Murata J., Fujita Y., Shimizu H. Prolonged elevation of serum granulysin in drug-induced hy-persensitivity syndrome. Br. J. Dermatol. 2012;167:452–453. doi: 10.1111/j.1365-2133.2012.10921.x. (PubMed) (CrossRef) (Google Scholar)
Su S.-C., Mockenhaupt M., Wolkenstein P., Dunant A., le Gouvello S., Chen C.-B., Chosidow O., Valeyrie-Allanore L., Bellon T., Sekula P., et al. Interleukin-15 Is Associated with Severity and Mortality in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. J. Investig. Dermatol. 2017;137:1065–1073. doi: 10.1016/j.jid.2016.11.034. (PubMed) (CrossRef) (Google Scholar)
Hasegawa A., Shinkuma S., Hayashi R., Hama N., Watanabe H., Kinoshita M., Ogawa Y., Abe R. 019 Serum RIP3 level as a severi-ty-predictive marker for Stevens-Johnson syndrome and Toxic Epidermal Necrolysis. J. Investig. Dermatol. 2019;139:S4. doi: 10.1016/j.jid.2019.03.095. (CrossRef) (Google Scholar)
Hasegawa A., Shinkuma S., Hayashi R., Hama N., Watanabe H., Kinoshita M., Ogawa Y., Abe R. RIP3 as a diagnostic and severity marker for Stevens-Johnson syndrome and Toxic Epidermal Necrolysis. J. Allergy Clin. Immunol. Pract. 2020;8:1768–1771.e7. doi: 10.1016/j.jaip.2020.01.006. (PubMed) (CrossRef) (Google Scholar)
Saito N., Qiao H., Yanagi T., Shinkuma S., Nishimura K., Suto A., Fujita Y., Suzuki S., Nomura T., Nakamura H., et al. An annexin A1-FPR1 interaction contributes to necrop-tosis of keratinocytes in severe cutaneous adverse drug reactions. Sci. Transl. Med. 2014;6:245ra95. doi: 10.1126/scitranslmed.3008227. (PubMed) (CrossRef) (Google Scholar)
Abate M.S., Battle L.R., Emerson A.N., Gardner J.M., Shalin S.C. Dermatologic Urgencies and Emergencies: What Every Pathologist Should Know. Arch. Pathol. Lab. Med. 2019;143:919–942. doi: 10.5858/arpa.2018-0239-RA. (PubMed) (CrossRef) (Google Scholar)
Kerl K., Kerl H. Severe cutaneous adverse drug reactions. Diagn. Histopathol. 2020;27:1–5. doi: 10.1016/j.mpdhp.2020.10.008. (CrossRef) (Google Scholar)
Lin C.-C., Chen C.-B., Wang C.-W., Hung S.-I., Chung W.-H. Stevens-Johnson syndrome and Toxic Epidermal Necrolysis: Risk factors, causality assessment and poNETtial prevention strategies. Expert Rev. Clin. Immunol. 2020;16:373–387. doi: 10.1080/1744666X.2020.1740591. (PubMed) (CrossRef) (Google Scholar)
Garcia-Doval I., LeCleach L., Bocquet H., Otero X.L., Roujeau J.C. Toxic epidermal necrolysis and Stevens-Johnson syndrome: Does early withdrawal of causative drugs decrease the risk of death? Arch. Dermatol. 2000;136:323–327. doi: 10.1001/archderm.136.3.323. (PubMed) (CrossRef) (Google Scholar)
Cavkaytar O., Kuyucu S. An Update on the Management of Severe Cutaneous Drug Hypersensitivity Reactions. Curr. Pharm. Des. 2019;25:3881–3901. doi: 10.2174/1381612825666191106115556. (PubMed) (CrossRef) (Google Scholar)
Gallagher R.M., Kirkham J.J., Mason J.R., Bird K.A., Williamson P.R., Nunn A.J., Turner M.A., Smyth R.L., Pirmohamed M. Development and inter-rater reliability of the Liverpool adverse drug reaction causality assessment tool. PLoS ONE. 2011;6:e28096. doi: 10.1371/journal.pone.0028096. (PMC free article) (PubMed) (CrossRef) (Google Scholar)
Coias J.L., Abbas L.F., Cardones A.R. Management of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Review and Update. Curr. Dermatol. Rep. 2019;8:219–233. doi: 10.1007/s13671-019-00275-0. (CrossRef) (Google Scholar)
Hu C.-H., Chang N.-J., Liu E.-W., Chuang S.-S., Chung W.-H., Yang J.-Y. SCORTEN and impaired renal function related to mortality of Toxic Epidermal Necrolysis syndrome patients in the Asian population. J. Eur. Acad. Dermatol. Venereol. 2012;27:628–633. doi: 10.1111/j.1468-3083.2012.04502.x. (PubMed) (CrossRef) (Google Scholar)
Torres-Navarro I., Briz-Redón Á., Botella-Estrada R. Accuracy of SCORTEN to predict the prognosis of Stevens-Johnson syn-drome/Toxic Epidermal Necrolysis: A systematic review and meta-analysis. J. Eur. Acad. Dermatol. Venereol. 2020;34:2066–2077. doi: 10.1111/jdv.16137. (PubMed) (CrossRef) (Google Scholar)
Imahara S.D., Holmes J.H., Heimbach D.M., Engrav L.E., Honari S., Klein M.B., Gibran N. SCORTEN Overestimates Mortality in the Setting of a Standardized Treatment Protocol. J. Burn. Care Res. 2006;27:270–275. doi: 10.1097/01.BCR.0000216532.71360.9B. (PubMed) (CrossRef) (Google Scholar)
Micheletti R.G., Chiesa-Fuxench Z., Noe M.H., Stephen S., Aleshin M., Agarwal A., Boggs J., Cardones A.R., Chen J.K., Cotliar J., et al. Stevens-Johnson Syndrome/Toxic Epi-dermal Necrolysis: A Multicenter Retrospective Study of 377 Adult Patients from the United States. J. Investig. Dermatol. 2018;138:2315–2321. doi: 10.1016/j.jid.2018.04.027. (PubMed) (CrossRef) (Google Scholar)
Noe M.H., Rosenbach M., Hubbard R.A., Mostaghimi A., Cardones A.R., Chen J.K., Cotliar J., Davis M.D.P., Dominguez A., Fox L.P., et al. Development and Validation of a Risk Prediction Model for In-Hospital Mortality Among Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necroly-sis-ABCD-10. JAMA Dermatol. 2019;155:448–454. doi: 10.1001/jamadermatol.2018.5605. (PMC free article) (PubMed) (CrossRef) (Google Scholar)
Torres-Navarro I., Briz-Redón Á., Botella-Casas G., Sahuquillo-Torralba A., Calle-Andrino A., de Unamuno-Bustos B., Piqueras-García J., Ginés J.R., Tapial J.M., de Miquel V.A., et al. Accuracy of SCORTEN and ABCD-10 to predict mortality and the influence of renal function in Stevens–Johnson syn-drome/Toxic Epidermal Necrolysis. J. Dermatol. 2020;47:1182–1186. doi: 10.1111/1346-8138.15490. (PubMed) (CrossRef) (Google Scholar)
Creamer D., Walsh S.A., Dziewulski P., Exton L.S., Lee H.Y., Dart J.K.G., Setterfield J., Bunker C.B., Ardern-Jones M.R., Watson K.M.T., et al. UK guidelines for the management of Ste-vens-Johnson syndrome/Toxic Epidermal Necrolysis in adults 2016. J. Plast. Reconstr. Aesthetic Surg. 2016;69:e119–e153. doi: 10.1016/j.bjps.2016.01.034. (PubMed) (CrossRef) (Google Scholar)
McCullough M., Burg M., Lin E., Peng D., Garner W. Steven Johnson Syndrome and Toxic Epidermal Necrolysis in a burn unit: A 15-year experience. Burn. 2017;43:200–205. doi: 10.1016/j.burns.2016.07.026. (PubMed) (CrossRef) (Google Scholar)
McPherson T., Exton L.S., Biswas S., Creamer D., Dziewulski P., Newell L., Tabor K.L., Wali G.N., Walker G., Walker R., et al. British Association of Dermatologists’ guide-lines for the management of Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis in children and young people. Br. J. Dermatol. 2019;181:37–54. doi: 10.1111/bjd.17841. (PubMed) (CrossRef) (Google Scholar)
Tapia B., Padial A., Sánchez-Sabaté E., Alvarez-Ferreira J., Morel E., Blanca M., Bellón T. Involvement of CCL27-CCR10 interactions in drug-induced cutaneous reactions. J. Allergy Clin. Immunol. 2004;114:335–340. doi: 10.1016/j.jaci.2004.04.034. (PubMed) (CrossRef) (Google Scholar)
Wang F., Ye Y., Luo Z.Y., Gao Q., Luo D.Q., Zhang X. Diverse expression of TNF-α and CCL27 in serum and blister of Ste-vens-Johnson syndrome/Toxic Epidermal Necrolysis. Clin. Transl. Allergy. 2018;8:1–6. doi: 10.1186/s13601-018-0199-6. (PMC free article) (PubMed) (CrossRef) (Google Scholar)
Hama N., Nishimura K., Hasegawa A., Yuki A., Kume H., Adachi J., Kinoshita M., Ogawa Y., Nakajima S., Nomura T., et al. Galectin-7 as a poNETtial biomarker of Ste-vens-Johnson syndrome/Toxic Epidermal Necrolysis: Identification by targeted proteomics using causative drug-exposed peripheral blood cells. J. Allergy Clin. Immunol. Pract. 2019;7:2894–2897.e7. doi: 10.1016/j.jaip.2019.05.002. (PubMed) (CrossRef) (Google Scholar)
Kim S.K., Kim W.J., Yoon J.H., Ji J.H., Morgan M.J., Cho H., Kim Y.C., Kim Y.-S. Upregulated RIP3 Expression PoNETtiates MLKL Phosphoryla-tion-Mediated Programmed Necrosis in Toxic Epidermal Necrolysis. J. Investig. Dermatol. 2015;135:2021–2030. doi: 10.1038/jid.2015.90. (PubMed) (CrossRef) (Google Scholar)
Canavan T.N., Mathes E.F., Frieden I., Shinkai K. Mycoplasma pneumoniae–induced rash and mucositis as a syndrome distinct from Stevens-Johnson syndrome and erythema multiforme: A systematic review. J. Am. Acad. Dermatol. 2015;72:239–245.e4. doi: 10.1016/j.jaad.2014.06.026. (PubMed) (CrossRef) (Google Scholar)
Gámez-González L.B., Peña-Varela C., Ramírez-López J.M., Yamazaki-Nakashimada M.A. Adenoviral-induced rash and mu-cositis: Expanding the spectrum of reactive infectious mucocutaneous eruption. Pediatric Dermatol. 2020;38:306–308. doi: 10.1111/pde.14419. (PubMed) (CrossRef) (Google Scholar)
Goyal A., Hook K. Two pediatric cases of influenza B-induced rash and mucositis: Stevens-Johnson syndrome or expansion of the Mycoplasma pneumoniae -induced rash with mucositis (MIRM) spectrum? Pediatr. Dermatol. 2019;36:929–931. doi: 10.1111/pde.13921. (PubMed) (CrossRef) (Google Scholar)
Mayor-Ibarguren A., Feito-Rodriguez M., González-Ramos J., del Rosal-Rabes T., González-Sainz F.J., Sánchez-Orta A., de Lucas-Laguna R. Mucositis Secondary to Chlamydia pneumoniae Infection: Expanding the Mycoplasma pneumoniae–Induced Rash and Mu-cositis Concept. Pediatric Dermatol. 2017;34:465–472. doi: 10.1111/pde.13140. (PubMed) (CrossRef) (Google Scholar)
Ramien M., Goldman J.L. Pediatric SSJ-NET: Where are we now? F1000Research. 2020;9:982. doi: 10.12688/f1000research.20419.1. (PMC free article) (PubMed) (CrossRef) (Google Scholar)
Ramien M.L., Bahubeshi A., Eichenfield L., Lara-Corrales I., Nopper A.J., Pope E., Levy M.L., Shear N.H. Redefining severe cutaneous reactions in children. Pediatric Dermatol. 2018;35:716–717. (Google Scholar)
Ramien M., Bruckner A.L. Mucocutaneous Eruptions in Acutely Ill Pediatric Patients—Think of Mycoplasma pneumoniae (and Other Infections) First. JAMA Dermatol. 2020;156:124. doi: 10.1001/jamadermatol.2019.3589. (PubMed) (CrossRef) (Google Scholar)
Ramien M.L. Reactive infectious mucocutaneous eruption: Mycoplasma pneumoniae -induced rash and mucositis and other parainfectious eruptions. Clin. Exp. Dermatol. 2021;46:420–429. doi: 10.1111/ced.14404. (PubMed) (CrossRef) (Google Scholar)
Miller M.M., Kamath S., Hughes M., Harter N., Luu M. Evaluation of Etanercept for Treatment of Reactive Infectious Mucocu-taneous Eruption. JAMA Dermatol. 2021;157:230–232. doi: 10.1001/jamadermatol.2020.5166. (PMC free article) (PubMed) (CrossRef) (Google Scholar)
Gupta L.K., Martin A.M., Agarwal N., D’Souza P., Das S., Kumar R., Pande S., Das N.K., Kumareshan M., Kumar P., et al. Guidelines for the management of Stevens-Johnson syndrome/Toxic Epidermal Necrolysis: An Indian perspective. Indian J. Dermatol. Venereol. Leprol. 2016;82:603–625. doi: 10.4103/0378-6323.191134. (PubMed) (CrossRef) (Google Scholar)
Schneider J.A., Cohen P.R. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Concise Review with a Compre-hensive Summary of Therapeutic Interventions Emphasizing Supportive Measures. Adv. Ther. 2017;34:1235–1244. doi: 10.1007/s12325-017-0530-y. (PMC free article) (PubMed) (CrossRef) (Google Scholar)
Liotti L., Caimmi S., Bottau P., Bernardini R., Cardinale F., Saretta F., Francesca M., Giuseppe C., Fabrizio F., Carlo C. Clinical features, outcomes and treatment in chil-dren with drug induced Stevens-Johnson syndrome and Toxic Epidermal Necrolysis. Acta Biomed. 2019;90:52–60. (PMC free article) (PubMed) (Google Scholar)
Palmieri T.L., Greenhalgh D.G., Saffle J.R., Spence R.J., Peck M.D., Jeng J.C., Mozingo D.W., Yowler C.J., Sheridan R.L., Ahrenholz D.H., et al. A multicenter review of toxic epidermal necroly-sis treated in U.S. burn centers at the end of the twentieth century. J. Burn Care Rehabil. 2002;23:87–96. doi: 10.1097/00004630-200203000-00004. (PubMed) (CrossRef) (Google Scholar)
Dorafshar A.H., Dickie S.R., Cohn A.B., Aycock J.K., O’Connor A., Tung A., Gottlieb L. Antishear therapy for Toxic Epidermal Necrolysis: An alternative treatment approach. Plast. Reconstr. Surg. 2008;122:154–160. doi: 10.1097/PRS.0b013e3181773d5d. (PubMed) (CrossRef) (Google Scholar)
Jaller J.A., McLellan B.N., Balagula Y. Wound Management in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Curr. Dermatol. Rep. 2020;9:58–72. doi: 10.1007/s13671-020-00285-3. (CrossRef) (Google Scholar)
Chafranska L., Saunte D.M., Behrendt N., Nygaard U., ChrisNETsen R.J., Sand C., Jemec G.B. Pediatric Toxic Epidermal Necrolysis treated successfully with infliximab. Pediatric Dermatol. 2019;36:342–345. doi: 10.1111/pde.13778. (PubMed) (CrossRef) (Google Scholar)
Gutiérrez Nava, M. A., Villarreal Hernández, O., Nieto Vargas, N. D., Martínez Cárdenas, K., Serafin Badillo, M., & García Piceno, Y. (2024). Retos, Horizontes y Conceptualización de la Salud Intercultural. Estudios Y Perspectivas Revista Científica Y Académica , 4(1), 241–261. https://doi.org/10.61384/r.c.a.v4i1.98
Tama Sánchez, M. A., Quiroz Mendoza, I. U., Medina Paredes, E., Paredes Romero, J. E., & Haro Baque, C. V. (2024). Síndrome de C.R.E.S.T. Presentación de un Caso. Descripción breve de la Patología. Revista Científica De Salud Y Desarrollo Humano, 5(1), 01–13. https://doi.org/10.61368/r.s.d.h.v5i1.69
Gutiérrez Nava, M. A., Villarreal Hernández, O., Nieto Vargas, N. D., Martínez Cárdenas, K., Serafin Badillo, M., & García Piceno, Y. (2024). Retos, Horizontes y Conceptualización de la Salud Intercultural. Estudios Y Perspectivas Revista Científica Y Académica , 4(1), 241–261. https://doi.org/10.61384/r.c.a.v4i1.99
Da Silva Santos , F., & López Vargas , R. (2020). Efecto del Estrés en la Función Inmune en Pacientes con Enfermedades Autoinmunes: una Revisión de Estudios Latinoamericanos. Revista Científica De Salud Y Desarrollo Humano, 1(1), 46–59. https://doi.org/10.61368/r.s.d.h.v1i1.9
Nassim J.S., Karim S.A., Grenier P., Schmidt B., Jones K.M. Infantile Toxic Epidermal Necrolysis: Successful treatment of an 8-week-old with intravenous immunoglobulin and amniotic membrane transplant. Pediatric Dermatol. 2021;38:202–205. doi: 10.1111/pde.14376. (PubMed) (CrossRef) (Google Scholar)
Wang R., Zhong S., Tu P., Li R., Wang M. Rapid remission of Stevens-Johnson syndrome by combination therapy using etanercept and intravenous immunoglobulin and a review of the literature. Dermatol. Ther. 2019;32:e12832. doi: 10.1111/dth.12832. (PubMed) (CrossRef) (Google Scholar)
Coulombe J., Belzile E., Duhamel A., Rault P., Buteau C., Debruycker J.-J., Bussières J.-F. Pediatric SSJ/NET Subdued by a Combination of Dexamethasone, Cyclosporine, and Etanercept. J. Cutan. Med. Surg. 2019;23:547–550. doi: 10.1177/1203475419861078. (PubMed) (CrossRef) (Google Scholar)
Michaels B., del Rosso J.Q. The role of systemic corticosteroid therapy in erythema multiforme major and stevens-johnson syndrome a review of past and current opinions. J. Clin. Aesthetic Dermatol. 2009;2:51. (PMC free article) (PubMed) (Google Scholar)
Zimmermann S., Sekula P., Venhoff M., Motschall E., Knaus J., Schumacher M., Mockenhaupt M. Systemic Immunomodulating Therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta-analysis. JAMA Dermatol. 2017;153:514–522. doi: 10.1001/jamadermatol.2016.5668. (PMC free article) (PubMed) (CrossRef) (Google Scholar)
Huang Y.-C., Li Y.-C., Chen T.-J. The efficacy of intravenous immunoglobulin for the treatment of Toxic Epidermal Necrolysis: A systematic review and meta-analysis. Br. J. Dermatol. 2012;167:424–432. doi: 10.1111/j.1365-2133.2012.10965.x. (PubMed) (CrossRef) (Google Scholar)
Lee H.Y., Lim Y.L., Thirumoorthy T., Pang S.M. The role of intravenous immunoglobulin in Toxic Epidermal Necrolysis: A ret-rospective analysis of 64 patients managed in a specialized centre. Br. J. Dermatol. 2013;169:1304–1309. doi: 10.1111/bjd.12607. (PubMed) (CrossRef) (Google Scholar)
Gilbert M., Scherrer L.A. Efficacy and safety of cyclosporine in Stevens-Johnson syndrome and Toxic Epidermal Necrolysis. Dermatol. Ther. 2019;32:e12758. doi: 10.1111/dth.12758. (PubMed) (CrossRef) (Google Scholar)
González-Herrada C., Rodríguez-Martín S., Cachafeiro L., Lerma V., González O., Lorente J.A., Rodríguez-Miguel A., González-Ramos J., Roustan G., Ramírez E., et al. Cyclosporine Use in Epidermal Necrolysis Is Associated with an Important Mortality Reduction: Evidence from Three Different Approaches. J. Investig. Dermatol. 2017;137:2092–2100. doi: 10.1016/j.jid.2017.05.022. (PubMed) (CrossRef) (Google Scholar)
Ng Q.X., De Deyn M.L.Z.Q., Venkatanarayanan N., Ho C.Y.X., Yeo W.-S. A meta-analysis of cyclosporine treatment for Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis. J. Inflamm. Res. 2018;11:135–142. doi: 10.2147/JIR.S160964. (PMC free article) (PubMed) (CrossRef) (Google Scholar)
Chen Y.-T., Hsu C.-Y., Chien Y.-N., Lee W.-R., Huang Y.-C. Efficacy of cyclosporine for the treatment of Stevens-Johnson syndrome and Toxic Epidermal Necrolysis: Systemic review and meta-analysis. Dermatol. Sin. 2017;35:131–137. doi: 10.1016/j.dsi.2017.04.004. (CrossRef) (Google Scholar)
Tsai T.Y., Huang I.H., Chao Y.C., Li H., Hsieh T.S., Wang H.H., Huang Y.T., Chen C.Y., Cheng Y.C., Kuo P.H., et al. Treating Toxic Epidermal Necrolysis with systemic immunomodulating therapies: A systematic review and network meta-analysis. J. Am. Acad. Dermatol. 2021;84:390–397. doi: 10.1016/j.jaad.2020.08.122. (PubMed) (CrossRef) (Google Scholar)
Fernandez A.P., Kerdel F.A. The use of i.v. IG therapy in dermatology. Dermatol. Ther. 2007;20:288–305. doi: 10.1111/j.1529-8019.2007.00142.x. (PubMed) (CrossRef) (Google Scholar)
Han F., Zhang J., Guo Q., Feng Y., Gao Y., Guo L., Hou Y., An J., Wang X., Yan B., et al. Successful treatment of Toxic Epidermal Necrolysis using plasmaphere-sis: A prospective observational study. J. Crit. Care. 2017;42:65–68. doi: 10.1016/j.jcrc.2017.07.002. (PubMed) (CrossRef) (Google Scholar)
Zhang S., Tang S., Li S., Pan Y., Ding Y. Biologic TNF-alpha inhibitors in the treatment of Stevens-Johnson syndrome and Toxic Epidermal Necrolysis: A systemic review. J. Dermatol. Treat. 2020;31:66–73. doi: 10.1080/09546634.2019.1577548. (PubMed) (CrossRef) (Google Scholar)
Wang C.-W., Yang L.-Y., Chen C.-B., Ho H.-C., Hung S.-I., Yang C.-H., Chang C.-J., Su S.-C., Hui R.C.-Y., Chin S.-W., et al. Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions. J. Clin. Investig. 2018;128:985–996. doi: 10.1172/JCI93349. (PMC free article) (PubMed) (CrossRef) (Google Scholar)
Derechos de autor 2024 Laura Kamila Pérez Alquichire, Jesús David González Martínez , Karina Estefany González Fuentes , Jesus Enrique Palacios Caicedo, Danuil Julián Melo Ascanio, Emilena Hernandez, Danuil Julián Melo Ascanio, Emilena Hernandez, Corina Villareal, Erika Durán, Maritza Johanna Camacho Santamaria
Esta obra está bajo licencia internacional Creative Commons Reconocimiento 4.0.
.jpg)
.png)
